Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M200, Carboplatin, Paclitaxel · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Escalating doses of volociximab at 10, 20, and 30 (or 15) mg/kg with carboplatin and paclitaxel. |
| Name | Type | Description |
|---|---|---|
| M200 (Volociximab), Carboplatin, Paclitaxel | DRUG | Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin. |
Inclusion Criteria 1. Males and females at least 18 years of age. 2. Stage IIIB or IV or recurrent NSCLC. 3. Measurable and/or evaluable disease according to RECIST. 4. No prior chemotherapy, biological therapy or immunotherapy for Stage IIIB/IV disease. Adjuvant therapy for early stage disease mus...
Top 20 of 84 competitors
M200 is an investigational small molecule being studied for the treatment of non-small cell lung cancer, ovarian cancer, and primary peritoneal cancer. It is in Phase 1 clinical development and has not been approved by the FDA.
M200 is being developed by AbbVie Inc. (ticker: ABBV). The drug is currently in Phase 1 clinical trials for oncology indications.
M200 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials for M200 have been completed.
M200 has been studied in two completed Phase 1 trials: NCT00635193, which evaluated M200 in combination with liposomal doxorubicin in ovarian cancer and primary peritoneal cancer, and NCT00654758, which studied M200 with carboplatin and paclitaxel in non-small cell lung cancer.
Yes, M200 is also known as volociximab. Clinical trial NCT00635193 is titled 'Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)', confirming that M200 and volociximab refer to the same drug.